Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / TAK - Eli Lilly's $3.2B Morphic Deal Is 'Crucial' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst | Benzinga

TAK - Eli Lilly's $3.2B Morphic Deal Is 'Crucial' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst | Benzinga

Takeda Pharmaceutical Company Limited American Depositary Shares

Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.

Lead asset MORF-057 is a small-molecule inhibitor that is currently in Phase 2b trial for ulcerative colitis, with a readout expected in the first half of 2025. It recently initiated a Phase 2 study in Crohn’s disease.

Also Read: Eli Lilly’s Alzheimer’s Therapy’s Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst.

Goldman Sachs writes that Takeda Pharmaceutical Company Ltd’s (NYSE:TAK) Entyvio generated $5.3 billion ...

Full story available on Benzinga.com
Stock Information
Company Name: Takeda Pharmaceutical Company Limited American Depositary Shares
Stock Symbol: TAK
Market: NYSE
Website: takeda.com
Menu
TAK TAK Quote TAK Short TAK News TAK Articles TAK Message Board
Get TAK Alerts

News, Short Squeeze, Breakout and More Instantly...